Tìm theo
Bicalutamide
Các tên gọi khác (1) :
  • Casodex
Thuốc chống ung thư và tác động vào hệ thống miễn dịch
Thuốc Gốc
Small Molecule
CAS: 90357-06-5
ATC: L02BB03
ĐG : Accord Healthcare , http://www.accord-healthcare.com
CTHH: C18H14F4N2O4S
PTK: 430.373
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C18H14F4N2O4S
Phân tử khối
430.373
Monoisotopic mass
430.061040456
InChI
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
InChI Key
InChIKey=LKJPYSCBVHEWIU-UHFFFAOYSA-N
IUPAC Name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide
Traditional IUPAC Name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide
SMILES
CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
Độ tan chảy
191-193 °C
Độ hòa tan
5 mg/L
logP
2.5
logS
-4.7
pKa (strongest acidic)
11.95
pKa (Strongest Basic)
-4
PSA
107.26 Å2
Refractivity
96.59 m3·mol-1
Polarizability
36.68 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
5
H Bond Donor Count
2
Physiological Charge
0
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
pKa
12.0
Dược Lực Học : Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Cơ Chế Tác Dụng : Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor. Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Dược Động Học :
▧ Absorption :
Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.
▧ Protein binding :
96%
▧ Metabolism :
Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation.
▧ Half Life :
5.9 days
▧ Clearance :
* Apparent oral cl=0.32 L/h [Normal Males]
Chỉ Định : For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Tương Tác Thuốc :
  • Budesonide CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of budesonide. The clinical significance of this interaction is greater for oral budesonide than for orally inhaled budesonide. Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.
  • Colchicine CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of colchicine. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function.
  • Eplerenone CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of eplerenone. A lower starting dose of eplerenone (25 mg once daily) is recommended in patients with hypertension who are also taking drugs that are moderate inhibitors of CYP3A4.
  • Everolimus CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of everolimus. Consider therapy modification. Recommendations regarding optimal management of this interaction vary according to specific indication and product used.
  • Fentanyl CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification.
  • Halofantrine CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).
  • Lurasidone CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor.
  • Ranolazine CYP3A4 inhibitors like ranolazine may increase the serum concentration of ranolazine. Consider therapy modification.
  • Tolvaptan CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of tolvaptan. This combination is contraindicated.
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Casodex
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01128
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=2375
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505386
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C08160
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00961
ChemSpider
http://www.chemspider.com/Chemical-Structure.50614.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18678
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0378-7017-93
PharmGKB
http://www.pharmgkb.org/drug/PA164746255
Wikipedia
http://en.wikipedia.org/wiki/Bicalutamide
RxList
http://www.rxlist.com/cgi/generic3/bicalutamide.htm
Drugs.com
http://www.drugs.com/cdi/bicalutamide.html
... loading
... loading